ACR 70 Response

ACR 70 Response

A measure—based on American College of Rheumatology criteria—of at least a 70% improvement in the number of tender and swollen joints, and a 70% improvement in at least 3 of the following: the patient’s global assessment of disease status; the patient’s assessment of pain; the patient’s assessment of function—measured using the Stanford Health Assessment Questionnaire—the physician’s global assessment of disease status; serum C-reactive protein levels.
References in periodicals archive ?
Moreover, 35% of certolizumab-treated patients had an ACR 50 response at that point, and 20% had an ACR 70 response.
More patients treated with ACTEMRA also achieved major clinical response, defined as achieving an ACR 70 response for a continuous 24-week period, compared to MTX plus placebo.
Although the best response rates were in patients on continuous abatacept treatment, even those who at first didn't respond to the drug showed notable responses, with 46% having an ACR 70 response, 18% having an ACR 90 response, and 5% attaining disease inactivity.
Of 28 patients treated with this interleukin 1 receptor antagonist after failing a TNF blocker, only 8% achieved an ACR 20 response, and no patients achieved an ACR 50 or ACR 70 response, she said.
Rheumatoid Arthristis Response to Abatacept Greater Early in Disease Early disease (duration [less Long-standing disease (duration than or equal to]2 years) > 10 years) ACR 70 Response HAQ Score Improvement of [greater than or equal to]0.
In addition, more than one-third of the combination group had an ACR 70 response vs.
Major clinical response, defined as achieving an ACR 70 response for a continuous 24 week period, was achieved in seven percent and four percent in the ACTEMRA 8 mg/kg plus MTX, ACTEMRA 4 mg/kg plus MTX groups, respectively, compared with one percent in the MTX plus placebo group.
In addition, statistically significantly superior responses were also seen in ACR 50 response rates for the 5, 10 and 15 mg twice daily doses and in the ACR 70 response rates for the 10 and 15 mg twice-daily doses.
A major clinical response, defined as a continuous ACR 70 response for 6 months or more, has been seen in 134 (31%).
ACR 50 response rates are around 50% and 37%; ACR 70 response rates are 13% and 9%, respectively.
In this group at 24 weeks, 73% achieved an American College of Rheumatology (ACR) 20 response, 43% achieved an ACR 50 response, and 23% reached an ACR 70 response.